Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can You Still Use Surrogate Markers In A Crowded Drug Class? Sollpura Panel Recommends BMI, Weight Endpoints

Executive Summary

The troubles that Alnara Pharmaceuticals has had with its application for Sollpura (liprotamase) for exocrine pancreatic insufficiency signal the challenges that developers of other drugs in crowded classes may face at FDA.
Advertisement

Related Content

In A Manufacturing Dispute With FDA, Can A Sponsor Get Help From An Advisory Committee?
In A Manufacturing Dispute With FDA, Can A Sponsor Get Help From An Advisory Committee?
In A Manufacturing Dispute With FDA, Can A Sponsor Get Help From An Advisory Committee?
Sollpura's Future After No Vote From Panel Might Include More Trials, Adult Indication
Rezield Needs Advantage Over Synagis, Advisory Cmte. Tells MedImmune

Topics

Advertisement
UsernamePublicRestriction

Register

PS053027

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel